Gilead Sciences, Goldfinch To Work on Therapies for Kidney Disease
May 08 2019 - 8:28AM
Dow Jones News
By Michael Dabaie
Gilead Sciences Inc. (GILD) and Goldfinch Bio Inc. said
Wednesday they would develop and commercialize therapeutics for
diabetic kidney disease and some orphan kidney diseases.
Under the multi-year collaboration, Gilead has exclusive options
to license worldwide rights to certain products directed toward
targets emerging from Goldfinch's Kidney Genome Atlas, a registry
of patients with kidney diseases.
Goldfinch will receive $55 million in upfront payments,
including a $5 million equity investment, and an additional $54
million to support the development of the KGA platform for diabetic
kidney disease. Goldfinch also is eligible for up to $1.95 billion
in potential payments for the first five collaboration programs
based on research, development, regulatory and commercial
milestones, and tiered royalties.
Gilead shares were down about 1% premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 08, 2019 08:13 ET (12:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024